|
End-of-day quote
Taipei Exchange
2026-09-15
|
5-day change | 1st Jan Change | ||
| 15.55 TWD | +1.63% |
|
-0.32% | -24.51% |
| 08-12 | Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-08 | Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Enimmune corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2,682 | 2,367 | 4,020 | 2,468 | 1,796 | 1,486 |
| Change | - | -11.74% | 69.85% | -38.63% | -27.21% | -17.27% |
| Enterprise Value (EV) 1 | 2,268 | 2,025 | 3,563 | 2,148 | 1,414 | 1,431 |
| Change | - | -10.71% | 75.92% | -39.7% | -34.18% | 1.22% |
| P/E | -31.9x | -49.9x | -15.7x | -11x | -11.3x | -9.04x |
| PBR | 4.34x | 4.15x | 7.38x | 7.66x | 4.8x | 9.93x |
| PEG | - | 1.1x | -0x | 0.9x | 0.3x | -2.58x |
| Capitalization / Revenue | 117x | 21.6x | 21.3x | 56.7x | 45x | 30.8x |
| EV / Revenue | 99.2x | 18.4x | 18.9x | 49.4x | 35.4x | 29.7x |
| EV / EBITDA | -29.9x | -40.4x | -12.8x | -9.04x | -9.72x | -7.99x |
| EV / EBIT | -27.4x | -34.5x | -12.4x | -8.82x | -9.36x | -7.73x |
| EV / FCF | -25.2x | -32.7x | -27.9x | -40.3x | -19x | -13.3x |
| FCF Yield | -3.96% | -3.06% | -3.59% | -2.48% | -5.27% | -7.49% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.4 | -0.79 | -3.882 | -3.4 | -2.203 | -2.28 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 22.88 | 109.8 | 188.4 | 43.49 | 39.92 | 48.19 |
| EBITDA 1 | -75.77 | -50.18 | -278.2 | -237.7 | -145.5 | -179.2 |
| EBIT 1 | -82.72 | -58.67 | -286.4 | -243.5 | -151.1 | -185.2 |
| Net income 1 | -74.45 | -47.25 | -248 | -223.7 | -157.5 | -164.3 |
| Net Debt 1 | -413.8 | -341.7 | -457.4 | -319.1 | -382 | -54.59 |
| Reference price 2 | 44.70 | 39.45 | 61.10 | 37.50 | 24.90 | 20.60 |
| Nbr of stocks (in thousands) | 60,000 | 60,000 | 65,800 | 65,800 | 72,134 | 72,134 |
| Announcement Date | 4/20/21 | 4/26/22 | 4/21/23 | 4/25/24 | 4/18/25 | 4/8/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 34.71M | |
| 20.63x | 7.28x | 14.62x | 1.44% | 70.24B | |
| 32.28x | 9.34x | 45.05x | 0.04% | 62.63B | |
| -76.7x | 14.8x | -71.37x | -.--% | 27.36B | |
| 29.77x | 6.32x | 16.41x | -.--% | 25.71B | |
| -15.03x | 5.62x | -7.06x | -.--% | 24.83B | |
| 26.45x | 5.03x | 16.73x | -.--% | 19.52B | |
| 44.88x | 16.47x | 33.42x | 0.34% | 15.51B | |
| 1267.62x | 36.68x | 797.93x | -.--% | 14.66B | |
| -15.8x | 3569.89x | -18.25x | -.--% | 14.69B | |
| Average | 146.01x | 407.94x | 91.94x | 0.2% | 27.52B | |
| Weighted average by Cap. | 77.53x | 200.44x | 52.40x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6564 Stock
- Valuation Enimmune corporation
Select your edition
All financial news and data tailored to specific country editions
